JP2019518788A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518788A5
JP2019518788A5 JP2019511816A JP2019511816A JP2019518788A5 JP 2019518788 A5 JP2019518788 A5 JP 2019518788A5 JP 2019511816 A JP2019511816 A JP 2019511816A JP 2019511816 A JP2019511816 A JP 2019511816A JP 2019518788 A5 JP2019518788 A5 JP 2019518788A5
Authority
JP
Japan
Prior art keywords
protein
protein according
seq
sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511816A
Other languages
English (en)
Japanese (ja)
Other versions
JP6997767B2 (ja
JP2019518788A (ja
Filing date
Publication date
Priority claimed from GBGB1608197.8A external-priority patent/GB201608197D0/en
Application filed filed Critical
Publication of JP2019518788A publication Critical patent/JP2019518788A/ja
Publication of JP2019518788A5 publication Critical patent/JP2019518788A5/ja
Application granted granted Critical
Publication of JP6997767B2 publication Critical patent/JP6997767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511816A 2016-05-10 2017-05-10 Cd200変異体及びその使用 Active JP6997767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
GB1608197.8 2016-05-10
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (3)

Publication Number Publication Date
JP2019518788A JP2019518788A (ja) 2019-07-04
JP2019518788A5 true JP2019518788A5 (enExample) 2020-06-25
JP6997767B2 JP6997767B2 (ja) 2022-03-04

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511816A Active JP6997767B2 (ja) 2016-05-10 2017-05-10 Cd200変異体及びその使用

Country Status (16)

Country Link
US (1) US11203628B2 (enExample)
EP (1) EP3455247A1 (enExample)
JP (1) JP6997767B2 (enExample)
KR (2) KR102498901B1 (enExample)
CN (1) CN109219614B (enExample)
AU (1) AU2017264825B2 (enExample)
BR (1) BR112018073280A2 (enExample)
CA (1) CA3023601A1 (enExample)
EA (1) EA201892554A1 (enExample)
GB (1) GB201608197D0 (enExample)
IL (1) IL262846B2 (enExample)
MX (1) MX386295B (enExample)
NZ (1) NZ747665A (enExample)
SG (1) SG11201809677XA (enExample)
WO (1) WO2017194941A1 (enExample)
ZA (1) ZA201807079B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
KR20250025619A (ko) * 2022-05-06 2025-02-24 두센티스 바이오테라퓨틱스 리미티드 신규한 cd200 융합 단백질
WO2023214387A1 (en) * 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2333802A (en) * 2000-11-22 2002-06-03 Transplantation Technologies I Truncated cd200
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2674578A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
EP2414385B1 (en) * 2009-03-31 2015-04-22 University of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
EP2523976B1 (en) * 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Similar Documents

Publication Publication Date Title
JP2019518788A5 (enExample)
Liang et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination
Shaik et al. Structural basis of coreceptor recognition by HIV-1 envelope spike
Carfı́ et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA
Huber et al. A specific domain in α-catenin mediates binding to β-catenin or plakoglobin
JP2019522466A5 (enExample)
JP5761831B2 (ja) 癌及び慢性感染の治療のための作動薬活性を有するil−2由来のポリペプチド
JP2019516665A5 (enExample)
JP2021500855A5 (enExample)
JP2019522465A5 (enExample)
JP2019521643A5 (enExample)
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
JP2013519721A5 (enExample)
JP2017537926A5 (enExample)
JP2015212284A5 (enExample)
Wang et al. Structural interaction and functional regulation of polycystin-2 by filamin
JP2014510519A5 (enExample)
Feng et al. Human β‐defensin‐3 structure motifs that are important in CXCR 4 antagonism
Palacín et al. Heteromeric amino acid transporters. In search of the molecular bases of transport cycle mechanisms
JP2019525764A5 (enExample)
Sette et al. A shared MHC supertype motif emerges by convergent evolution in macaques and mice, but is totally absent in human MHC molecules
CN116375880A (zh) 融合蛋白及其制备方法和应用
US20210057047A1 (en) In-silico method for designing a (d)-polypeptide ligand
CN116836260A (zh) 一种识别mage-a4的t细胞受体及其编码序列和应用